S&P Futures
6,036.75 -1.50 (-0.02%) Dow Futures
44,977.00 +26.00 (+0.06%) Nasdaq Futures
20,965.00 -28.50 (-0.14%) Russell 2000 Futures
2,435.10 +2.70 (+0.11%) Crude Oil
68.85 +0.08 (+0.12%) Gold
2,640.20 +18.90 (+0.72%)
Revive Therapeutics Ltd. (RVVTF)
| Previous Close | 0.0072 |
| Open | 0.0072 |
| Bid | 0.0065 x 0 |
| Ask | 0.0098 x 0 |
| Day's Range | 0.0072 - 0.0072 |
| 52 Week Range | 0.0060 - 0.0360 |
| Volume | |
| Avg. Volume | 469,780 |
| Market Cap | 2.968M |
| Beta (5Y Monthly) | -0.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0100 |
| Earnings Date | Nov 27, 2024 - Dec 02, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireRevive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke
TORONTO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, medical countermeasures and rare disorders, today announced the publication of a scientific article demonstrating the potential of psilocybin as a novel therapeutic approach in stroke. The publication, entitled, “Neuroprotective effects of psiloc
- GlobeNewswire
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
TORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on the research study evaluating Bucillamine as a potential treatment for nerve agent exposure, in partnership with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Can
